会议强调，2026年继续实施好适度宽松的货币政策。把促进经济高质量发展、物价合理回升作为货币政 策的重要考量，灵活高效运用降准降息等多种货币政策工具，保持流动性充裕，保持社会融资条件相对 宽松，引导金融总量合理增长、信贷投放均衡，使社会融资规模、货币供应量增长同经济增长和价格总 水平预期目标相匹配。畅通货币政策传导机制，发挥好政策利率引导作用，做好利率政策执行和监督， 促进社会综合融资成本低位运行。有序扩大明示企业贷款综合融资成本工作覆盖面，推动明示个人贷款 综合融资成本。保持人民币汇率在合理均衡水平上的基本稳定，防范汇率超调风险。 会议指出，2025年，人民银行坚持专业务实精准，适度宽松的货币政策发力显效。强化中国人民银行政 策与市场关切的交集度和针对性，及时推出一揽子货币政策，综合运用降低存款准备金率、公开市场操 作等多种货币政策工具，保持流动性充裕。下调政策利率、结构性货币政策工具利率和个人住房公积金 贷款利率，促进降低社会综合融资成本。强化货币政策执行和监督，完善利率自律管理。不断完善货币 政策框架，引导货币市场利率围绕政策利率更平稳运行，加强市场沟通和预期引导。 北京商报讯（记者 廖蒙）1月6日，据 ...

Core Insights - The People's Bank of China (PBOC) held a work meeting on January 5-6, 2026, to summarize 2025's work, analyze the current situation, and plan for the "14th Five-Year" reform and development [1][2] Group 1: Legislative and Regulatory Focus - The meeting emphasized accelerating important legislative reforms, including the laws on the PBOC, financial stability, and commercial banks [1] - Key legislative projects for 2026 include constructing a financial statistical system and standard that aligns with a modern central banking system [2] - Strengthening regulations on virtual currency transactions and enhancing anti-money laundering measures were highlighted as critical areas of focus [1][2] Group 2: Financial Management and Support Policies - The PBOC plans to implement a one-time personal credit repair policy to support individuals in rebuilding their credit efficiently [1][2] - Continuous improvement of the social credit system and enhancing payment services for elderly individuals and foreign nationals in China are part of the agenda [2] - The meeting also discussed the importance of cash supply assurance and optimizing the management system for digital currency [1]

会议强调，2026年继续做好金融支持融资平台债务风险化解工作，稳妥有序推进融资平台退出。推进重 点地区和重点机构风险处置，强化中小金融机构风险识别和早期纠正。充分发挥中央银行宏观审慎管理 和维护金融稳定功能，完善宏观审慎和金融稳定管理工具箱。完善金融市场监测指标体系，探索开展金 融市场宏观审慎管理。建立在特定情景下向非银机构提供流动性的机制性安排，发挥好两项支持资本市 场的货币政策工具作用。强化金融市场监管执法，持续打击金融市场违法违规活动。 北京商报讯（记者 廖蒙）1月6日，据中国人民银行官网，2026年中国人民银行工作会议1月5日—6日召 开，会议总结了2025年工作，分析当前形势，研究中国人民银行"十五五"改革发展规划，部署2026年工 作。 在防范金融风险方面，会议指出，2025年重点领域金融风险持续收敛。金融市场保持稳定运行。优化支 持资本市场两项货币政策工具，坚定支持发挥汇金公司"类平准基金"作用，有效提振市场信心。加强债 券市场监测与预期引导，加大对债券市场违法违规行为查处力度。综合施策维护外汇市场稳健运行。金 融支持融资平台债务风险化解取得明显成效。重点机构和重点区域金融风险处置稳步推进。设立 ...

Core Viewpoint - The People's Bank of China (PBOC) emphasizes the need for continued financial reform and opening up in 2026, focusing on enhancing supervision and management across various financial markets and supporting the development of international financial centers [1] Group 1: Financial Reform and Supervision - The PBOC plans to strengthen supervision and management of interbank bond markets, money markets, foreign exchange markets, bill markets, gold markets, and related derivatives [1] - There will be a focus on enhancing the overall regulatory framework for financial infrastructure [1] Group 2: International Financial Centers - The PBOC aims to deepen high-level opening of financial markets and optimize mechanisms like "Bond Connect" and "Swap Connect" [1] - Support will be provided for the construction of the Shanghai International Financial Center while maintaining the stability and prosperity of the Hong Kong financial market [1] Group 3: Cross-Border Financial Services - The PBOC will facilitate the use of the Renminbi in trade and investment by enhancing the role of central bank currency swaps and improving cross-border financial services [1] - There will be efforts to improve the infrastructure for cross-border use of the Renminbi and welcome more eligible foreign entities to issue Panda bonds [1] - Expansion of the rapid payment system's interconnectivity and promotion of QR code interoperability cooperation are also planned [1]

北京商报讯（记者 宋亦桐）1月6日，国家金融监督管理总局陕西监管局公布的行政处罚信息公示表显 示，交通银行股份有限公司陕西省分行因"发放固定资产贷款不审慎、银行承兑汇票授信后管理不到 位、超过借款人实际需求发放流动资金贷款、项目贷款贷后管理不到位"违法违规行为，被罚款253万 元；监管机构对相关责任人员牛博、姚淑芳分别给予警告，对林雅欣给予警告并罚款5万元。 ...

北京商报讯（记者 孟凡霞 周义力）1月6日，国家金融监督管理总局海南监管局发布《关于海南农商银 行吸收合并保亭融兴村镇银行的批复》，同意海南农商银行吸收海南保亭融兴村镇银行，并承接海南保 亭融兴村镇银行清产核资后的资产、负债、业务以及其他各项权利义务。 ...

Core Viewpoint - The first IPO application for the ChiNext board in 2026 is set to be reviewed, with Hangzhou Gaote Electronics Co., Ltd. scheduled for examination on January 13, 2026 [1] Company Overview - Hangzhou Gaote Electronics is recognized as a national high-tech enterprise and a specialized and innovative "little giant" company, focusing on providing new energy industry products related to safe, reliable, efficient, stable, and economically viable battery management systems [1] IPO Details - The company’s IPO was accepted on June 23, 2025, and entered the inquiry stage on July 9, 2025 [1] - Gaote Electronics aims to raise 850 million yuan, which will be allocated to the construction of an intelligent manufacturing center for battery management systems and to supplement working capital after deducting issuance costs [1]

Core Viewpoint - Guanshang Technology (301213) plans to acquire 100% of Jinzhou Liaojing Electronic Technology Co., Ltd. through a combination of share issuance and cash payment, with the stock resuming trading on January 7 [1] Group 1: Acquisition Details - The transaction is expected to constitute a major asset restructuring and related party transaction, but it will not qualify as a restructuring listing [1] - The acquisition aims to enhance Guanshang Technology's ability to provide a one-stop solution of "core components + intelligent system platform + full life cycle management" to military and defense clients [1] Group 2: Strategic Implications - By acquiring Liaojing Electronic, which specializes in military semiconductor research and production, Guanshang Technology aims to strengthen customer loyalty and build significant competitive barriers [1] - The company anticipates that this move will expand its overall sales scale and further enhance its sustainable profitability and core competitiveness [1]

北京商报讯(记者丁宁)1月6日晚间，伟思医疗(688580)发布公告称，公司股票连续三个交易日内收盘价 格涨幅偏离值累计超过30%，属于股票交易异常波动。 因涉及脑机接口概念，伟思医疗已连续两个交易日涨停收盘，截至1月6日收盘，伟思医疗报69.7元/ 股，涨幅为20.01%。 伟思医疗表示，公司主营业务聚焦于康复医疗器械的研发、生产与销售，产品广泛应用于精神康复、盆 底及产后康复、神经康复等领域。截至2025年末，公司在脑机接口领域的新产品仍处于市场培育初期， 主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接口存在显著技术路径差异，相关产品尚未 实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

Core Viewpoint - Xuantai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is expected to enhance the company's product line and competitiveness, positively impacting future operating performance [1] Group 1 - The company announced the approval of injectable isavuconazole on January 6 [1] - The approval is seen as a strategic move to enrich the company's product offerings [1] - The introduction of this product is anticipated to have a positive effect on the company's future financial performance [1]